PF-114, a Novel Inhibitor of Bcr-Abl Chimeric Tyrosine Kinase, Attenuates Intracellular CrkL Phosphorylation and Kills Chronic Myeloid Leukemia Cells

PF-114, a Novel Inhibitor of Bcr-Abl Chimeric Tyrosine Kinase, Attenuates Intracellular CrkL Phosphorylation and Kills Chronic Myeloid Leukemia Cells

Background & Aims. The chimeric tyrosine kinase Bcr-Abl triggers malignant transformation of myeloid cells via phosphorylation of a number of substrates including the CrkL adaptor protein. Pharmacological inhibition of Bcr-Abl mediated signaling is a major strategy in treatment of patients with...

Full description

Bibliographic Details
Main Authors: ES Kolotova, VV Tatarskii, AA Zeifman, OV Stroganov, VS Stroilov, IYu Titov, FN Novikov, AA Kalinina, GG Chilov, AA Shtil’
Format: Article
Language:Russian
Published: Practical Medicine Publishing House 2016-01-01
Series:Kliničeskaâ onkogematologiâ
Subjects:
chronic myeloid leukemia
Bcr-Abl tyrosine kinase
protein phosphorylation
flow cytometry
cytotoxicity
Online Access:http://bloodjournal.ru/en/pf-114-a-novel-inhibitor-of-bcr-abl-chimeric-tyrosine-kinase-attenuates-intracellular-crkl-phosphorylation-and-kills-chronic-myeloid-leukemia-cells/

Internet

http://bloodjournal.ru/en/pf-114-a-novel-inhibitor-of-bcr-abl-chimeric-tyrosine-kinase-attenuates-intracellular-crkl-phosphorylation-and-kills-chronic-myeloid-leukemia-cells/

Similar Items